TN2011000220A1 - Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors - Google Patents
Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitorsInfo
- Publication number
- TN2011000220A1 TN2011000220A1 TN2011000220A TN2011000220A TN2011000220A1 TN 2011000220 A1 TN2011000220 A1 TN 2011000220A1 TN 2011000220 A TN2011000220 A TN 2011000220A TN 2011000220 A TN2011000220 A TN 2011000220A TN 2011000220 A1 TN2011000220 A1 TN 2011000220A1
- Authority
- TN
- Tunisia
- Prior art keywords
- pyridine
- phosphodiesterase
- inhibitors
- pyrimidine derivatives
- compounds
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11459508P | 2008-11-14 | 2008-11-14 | |
| US16621509P | 2009-04-02 | 2009-04-02 | |
| PCT/US2009/064643 WO2010057126A1 (fr) | 2008-11-14 | 2009-11-16 | Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2011000220A1 true TN2011000220A1 (en) | 2012-12-17 |
Family
ID=41557471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2011000220A TN2011000220A1 (en) | 2008-11-14 | 2011-05-05 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8318718B2 (fr) |
| EP (1) | EP2364306B1 (fr) |
| JP (1) | JP2012508777A (fr) |
| KR (1) | KR20110086603A (fr) |
| AR (1) | AR074343A1 (fr) |
| AU (1) | AU2009313773B2 (fr) |
| BR (1) | BRPI0921598A2 (fr) |
| CA (1) | CA2742833C (fr) |
| CR (1) | CR20110279A (fr) |
| EA (1) | EA201100749A1 (fr) |
| ES (1) | ES2413808T3 (fr) |
| IL (1) | IL212670A0 (fr) |
| MA (1) | MA32891B1 (fr) |
| MX (1) | MX2011005093A (fr) |
| TN (1) | TN2011000220A1 (fr) |
| TW (1) | TW201030001A (fr) |
| WO (1) | WO2010057126A1 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009316802B2 (en) | 2008-11-21 | 2015-02-26 | Vtv Therapeutics Llc | Adamantyl benzamide compounds |
| ME02337B (fr) | 2009-02-05 | 2016-06-20 | Takeda Pharmaceuticals Co | Composés pyridazinone |
| US8846713B2 (en) | 2010-06-24 | 2014-09-30 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors |
| JP5785548B2 (ja) | 2010-08-04 | 2015-09-30 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP5760085B2 (ja) * | 2010-08-04 | 2015-08-05 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| EP2604597B1 (fr) | 2010-08-10 | 2017-01-04 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique et utilisation de celui-ci comme inhibiteur de phosphodiesterase 10a |
| CA2824047C (fr) | 2011-01-11 | 2019-06-18 | Sunovion Pharmaceuticals Inc. | Composes heteroaryles et leurs procedes d'utilisation |
| MX2013009575A (es) | 2011-02-18 | 2014-10-14 | Exonhit Therapeutics Sa | Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a). |
| WO2012124782A1 (fr) | 2011-03-16 | 2012-09-20 | 武田薬品工業株式会社 | Composé hétérocyclique condensé |
| SG10201604682VA (en) * | 2011-06-10 | 2016-07-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| TWI570122B (zh) | 2011-06-22 | 2017-02-11 | 武田藥品工業股份有限公司 | 稠合雜環化合物之結晶 |
| PE20140868A1 (es) | 2011-06-24 | 2014-07-18 | Amgen Inc | Antagonistas trpm8 y su uso en tratamientos |
| CA2839703A1 (fr) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Antagonistes de trpm8 et leur utilisation dans le cadre therapeutique |
| UA109735C2 (xx) * | 2011-08-25 | 2015-09-25 | Піримідинові інгібітори pde10 | |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| WO2014071044A1 (fr) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a) |
| WO2014142322A1 (fr) | 2013-03-15 | 2014-09-18 | 第一三共株式会社 | Dérivé du benzothiophène |
| WO2015006689A1 (fr) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Traitement et diagnostic du cancer et d'états précancéreux à l'aide d'inhibiteurs de pde10a et procédés pour mesurer l'expression de pde10a |
| CA2925211A1 (fr) | 2013-09-27 | 2015-04-02 | Nimbus Iris, Inc. | Inhibiteurs d'irak et leurs utilisation |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| AU2015295248B2 (en) | 2014-07-31 | 2019-05-16 | Institut Pasteur Korea | 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin e synthase inhibitors |
| KR20180052635A (ko) | 2015-09-18 | 2018-05-18 | 가켄 세이야쿠 가부시키가이샤 | 바이아릴 유도체 및 이를 포함하는 약제 |
| CN110563664A (zh) * | 2019-07-23 | 2019-12-13 | 上海合全药物研发有限公司 | 外消旋体(4as,7s,7as)-叔丁基-7-羟基六氢环戊二烯[b][1,4]噁嗪-4(4ah)-甲酸基酯制法 |
| CN119119062A (zh) * | 2021-05-12 | 2024-12-13 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物 |
| WO2022238335A1 (fr) * | 2021-05-12 | 2022-11-17 | Boehringer Ingelheim International Gmbh | Dérivés de pyridine ayant des substituants cycliques liés à c en tant qu'inhibiteurs de cgas |
| KR102840252B1 (ko) * | 2023-04-27 | 2025-07-30 | 한국화학연구원 | 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198417A (en) | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
| JP2004536113A (ja) * | 2001-07-03 | 2004-12-02 | カイロン コーポレイション | チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物 |
| DE602004013314T2 (de) | 2003-04-04 | 2008-08-07 | H. Lundbeck A/S | 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6-tetrahydropyridin-derivate als serotonin-wiederaufnahme-hemmer |
| DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| DE10344223A1 (de) | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| DE10349587A1 (de) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| DE102005016634A1 (de) | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| JP2009503073A (ja) | 2005-08-02 | 2009-01-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての５−置換チアゾール−２−イルアミノ化合物および組成物 |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| US7868177B2 (en) * | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| WO2008057280A1 (fr) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Composés à cycles multiples et procédés d'utilisation |
| WO2009081259A1 (fr) | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Dérivés phénoxy-pyridylés |
| BRPI0914891A2 (pt) | 2008-06-20 | 2015-11-24 | Metabolex Inc | agonistas de aril gpr119 e usos dos mesmos |
-
2009
- 2009-11-13 AR ARP090104404A patent/AR074343A1/es not_active Application Discontinuation
- 2009-11-13 TW TW098138717A patent/TW201030001A/zh unknown
- 2009-11-16 EA EA201100749A patent/EA201100749A1/ru unknown
- 2009-11-16 AU AU2009313773A patent/AU2009313773B2/en not_active Ceased
- 2009-11-16 BR BRPI0921598A patent/BRPI0921598A2/pt not_active Application Discontinuation
- 2009-11-16 MX MX2011005093A patent/MX2011005093A/es active IP Right Grant
- 2009-11-16 CA CA2742833A patent/CA2742833C/fr not_active Expired - Fee Related
- 2009-11-16 US US12/619,573 patent/US8318718B2/en active Active
- 2009-11-16 WO PCT/US2009/064643 patent/WO2010057126A1/fr not_active Ceased
- 2009-11-16 ES ES09752706T patent/ES2413808T3/es active Active
- 2009-11-16 EP EP09752706.3A patent/EP2364306B1/fr active Active
- 2009-11-16 KR KR1020117013477A patent/KR20110086603A/ko not_active Withdrawn
- 2009-11-16 JP JP2011536570A patent/JP2012508777A/ja not_active Ceased
-
2011
- 2011-05-03 IL IL212670A patent/IL212670A0/en unknown
- 2011-05-05 TN TN2011000220A patent/TN2011000220A1/fr unknown
- 2011-05-26 CR CR20110279A patent/CR20110279A/es not_active Application Discontinuation
- 2011-06-10 MA MA33931A patent/MA32891B1/fr unknown
-
2012
- 2012-11-14 US US13/676,826 patent/US8759532B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2742833A1 (fr) | 2010-05-20 |
| CR20110279A (es) | 2011-09-22 |
| AU2009313773B2 (en) | 2013-03-21 |
| JP2012508777A (ja) | 2012-04-12 |
| ES2413808T3 (es) | 2013-07-17 |
| IL212670A0 (en) | 2011-07-31 |
| TW201030001A (en) | 2010-08-16 |
| MX2011005093A (es) | 2011-09-27 |
| EP2364306A1 (fr) | 2011-09-14 |
| US8759532B2 (en) | 2014-06-24 |
| AU2009313773A1 (en) | 2010-05-20 |
| MA32891B1 (fr) | 2011-12-01 |
| US8318718B2 (en) | 2012-11-27 |
| WO2010057126A1 (fr) | 2010-05-20 |
| CA2742833C (fr) | 2013-12-31 |
| EA201100749A1 (ru) | 2011-10-31 |
| US20130079325A1 (en) | 2013-03-28 |
| BRPI0921598A2 (pt) | 2016-02-10 |
| US20100125062A1 (en) | 2010-05-20 |
| AR074343A1 (es) | 2011-01-12 |
| KR20110086603A (ko) | 2011-07-28 |
| EP2364306B1 (fr) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2011000220A1 (en) | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | |
| TN2011000221A1 (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors | |
| TN2012000530A1 (en) | Nitrogen heterocyclic compounds useful as pde10 inhibitors | |
| MX2008011258A (es) | Derivados de quinazolina como inhibidores de fosfodiesterasa 10. | |
| MX2008010671A (es) | Derivados de cinolina como inhibidores de fosfodiesterasa 10. | |
| MX2008010953A (es) | Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10. | |
| WO2008128072A3 (fr) | Inhibiteurs de la kinase axl | |
| MX2010007392A (es) | Antagonistas de trpa1. | |
| UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
| MY151246A (en) | Benzofuranyl derivatives | |
| MX2009006535A (es) | Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina. | |
| WO2009006389A8 (fr) | Composés utiles en tant qu'inhibiteurs de la kinase raf | |
| ZA201000079B (en) | Organic compounds | |
| WO2009108383A3 (fr) | Dérivés de xanthine substitués | |
| MX2011007750A (es) | Composiciones y metodos para inhibicion de la ruta jak. | |
| MX2009010728A (es) | Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora. | |
| WO2009079008A8 (fr) | Benzopyranes et analogues utilisés comme inhibiteurs de la rho kinase | |
| MX2012004548A (es) | Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central. | |
| WO2009151598A8 (fr) | Diazacarbazoles et procédés d’utilisation | |
| MX2010007391A (es) | Antagonistas de trpa1. | |
| MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
| MX2008011175A (es) | Inhibidores de fosfodiesterasa 10. | |
| WO2011132051A3 (fr) | Composés tricycliques en tant qu'inhibiteurs de la phosphodiestérase-10 | |
| WO2010027424A3 (fr) | Derives de tylophorine a base de phenanthrene substitues en 9 | |
| GB2469980A (en) | Novel napthalimide-benzimidazole hybrids as potential antitumour agents and process for the preparation thereof |